Search results
Results from the WOW.Com Content Network
ATC code J05 Antivirals for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
List of Antiviral Drugs Antiviral Use Manufacturer Component Type Year approved Abacavir: HIV: ViiV Healthcare: Nucleoside analogue reverse transcriptase inhibitor (NRTI) 1998 Acyclovir (Aciclovir) Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 ...
A drug combination targeting SARS-CoV-2, Paxlovid, was approved in December 2021 to treat COVID-19. [12] It is a combination of nirmatrelvir , a protease inhibitor targeted to the SARS-CoV-2 3C-like protease , and ritonavir, which inhibits the metabolism of nirmatrelvir, thereby prolonging its effect.
BSAs are potential candidates for treatment of emerging and re-emerging viruses, such as ebola, marburg, and SARS-CoV-2. [3] [4] Many BSAs show antiviral activity against other viruses than originally investigated (such as remdesivir and interferon alfa). Efforts in drug repurposing for SARS-CoV-2 is currently underway.
On 11 February 2020, the International Committee on Taxonomy of Viruses adopted the official name "severe acute respiratory syndrome coronavirus 2" (SARS‑CoV‑2). [33] To avoid confusion with the disease SARS , the WHO sometimes refers to SARS‑CoV‑2 as "the COVID-19 virus" in public health communications [ 34 ] [ 35 ] and the name HCoV ...
As of July 2021, outpatient drugs budesonide and tocilizumab showed promising results in some patients but remained under investigation. [52] [53] [54] As of July 2021, a large number of drugs had been considered for treating COVID-19 patients. [55]
The DAA drugs against hepatitis C are taken orally, as tablets, for 8 to 12 weeks. [56] The treatment depends on the type or types of hepatitis C virus that are causing the infection. [57] Both during and at the end of treatment, blood tests are used to monitor the effectiveness of the treatment and subsequent cure. [56]
[43] [16] In December 2021, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for molnupiravir for the treatment of mild-to-moderate COVID‑19 in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID‑19, including hospitalization or death, and ...